Maria Gkotzamanidou

Athens, ESYE31, Greece

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer.

Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer.

Journal: Cancer research communications

Published: February 07, 2023

The Combination of Panobinostat and Melphalan for the Treatment of Patients with Multiple Myeloma.

The Combination of Panobinostat and Melphalan for the Treatment of Patients with Multiple Myeloma.

Journal: International journal of molecular sciences

Published: November 25, 2022

Targeting the Interplay between HDACs and DNA Damage Repair for Myeloma Therapy.

Targeting the Interplay between HDACs and DNA Damage Repair for Myeloma Therapy.

Journal: International journal of molecular sciences

Published: June 03, 2021

Patterns of Response to Immune Checkpoint Inhibitors in Association with Genomic and Clinical Features in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC).

Patterns of Response to Immune Checkpoint Inhibitors in Association with Genomic and Clinical Features in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC).

Journal: Cancers

Published: December 15, 2020

The DNA damage response network in the treatment of head and neck squamous cell carcinoma.

The DNA damage response network in the treatment of head and neck squamous cell carcinoma.

Journal: ESMO open

Published: December 04, 2020

Correction: Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma.

Correction: Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma.

Journal: British journal of cancer

Published: April 05, 2020

Prognostic impact of indoleamine 2,3-dioxygenase 1 (IDO1) mRNA expression on circulating tumour cells of patients with head and neck squamous cell carcinoma.

Prognostic impact of indoleamine 2,3-dioxygenase 1 (IDO1) mRNA expression on circulating tumour cells of patients with head and neck squamous cell carcinoma.

Journal: ESMO open

Published: November 23, 2019

Surrogates of immunologic cell death (ICD) and chemoradiotherapy outcomes in head and neck squamous cell carcinoma (HNSCC).

Surrogates of immunologic cell death (ICD) and chemoradiotherapy outcomes in head and neck squamous cell carcinoma (HNSCC).

Journal: Oral oncology

Published: February 12, 2019

DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7.

DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7.

Journal: Blood

Published: January 08, 2016

Neutrophil Gelatinase--Associated Lipocalin and Cystatin C Are Sensitive Markers of Renal Injury in Patients With Multiple Myeloma.

Neutrophil Gelatinase--Associated Lipocalin and Cystatin C Are Sensitive Markers of Renal Injury in Patients With Multiple Myeloma.

Journal: Clinical lymphoma, myeloma & leukemia

Published: July 27, 2015

Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma.

Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma.

Journal: British journal of cancer

Published: March 31, 2014

Hematologic response and stabilization of renal function in a patient with light chain deposition disease after lenalidomide treatment: a novel therapeutic approach?

Hematologic response and stabilization of renal function in a patient with light chain deposition disease after lenalidomide treatment: a novel therapeutic approach?

Journal: Clinical lymphoma, myeloma & leukemia

Published: December 28, 2013

Showing 1-12 of 26

Last Updated: 09/26/2026